SpringWorks Therapeutics (SWTX) Competitors $46.76 +0.01 (+0.02%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SWTX vs. ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, and ROIVShould you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. SpringWorks Therapeutics vs. Its Competitors Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Intra-Cellular Therapies (NASDAQ:ITCI) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability. Do insiders & institutionals believe in ITCI or SWTX? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 7.8% of SpringWorks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer ITCI or SWTX? Intra-Cellular Therapies received 416 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 67.95% of users gave SpringWorks Therapeutics an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% SpringWorks TherapeuticsOutperform Votes10667.95% Underperform Votes5032.05% Is ITCI or SWTX more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to SpringWorks Therapeutics' net margin of -134.73%. Intra-Cellular Therapies' return on equity of -9.93% beat SpringWorks Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% SpringWorks Therapeutics -134.73%-46.74%-41.12% Does the media favor ITCI or SWTX? In the previous week, SpringWorks Therapeutics had 2 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 2 mentions for SpringWorks Therapeutics and 0 mentions for Intra-Cellular Therapies. SpringWorks Therapeutics' average media sentiment score of 1.62 beat Intra-Cellular Therapies' score of 0.00 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral SpringWorks Therapeutics Very Positive Which has more risk and volatility, ITCI or SWTX? Intra-Cellular Therapies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Which has higher valuation and earnings, ITCI or SWTX? Intra-Cellular Therapies has higher revenue and earnings than SpringWorks Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64SpringWorks Therapeutics$219.67M16.04-$325.10M-$3.41-13.71 Do analysts rate ITCI or SWTX? Intra-Cellular Therapies presently has a consensus target price of $109.70, indicating a potential downside of 16.81%. SpringWorks Therapeutics has a consensus target price of $52.57, indicating a potential upside of 12.43%. Given SpringWorks Therapeutics' higher probable upside, analysts clearly believe SpringWorks Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17SpringWorks Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 SummaryIntra-Cellular Therapies beats SpringWorks Therapeutics on 11 of the 18 factors compared between the two stocks. Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SWTX vs. The Competition Export to ExcelMetricSpringWorks TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.52B$3.12B$5.61B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-13.4432.8927.2619.97Price / Sales16.04466.19412.06157.64Price / CashN/A168.6838.2534.64Price / Book4.673.417.064.69Net Income-$325.10M-$72.35M$3.24B$248.14M7 Day Performance-0.09%6.75%2.56%2.39%1 Month Performance1.39%17.19%8.75%6.06%1 Year Performance20.39%-17.58%31.30%13.57% SpringWorks Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SWTXSpringWorks Therapeutics1.5909 of 5 stars$46.76+0.0%$52.57+12.4%+20.1%$3.52B$219.67M-13.44230Positive NewsHigh Trading VolumeITCIIntra-Cellular Therapies0.9108 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.7568 of 5 stars$21.77+3.9%$39.17+79.9%-17.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics2.9041 of 5 stars$17.73-2.7%$37.40+110.9%+159.7%$13.17B$700K-63.32110Trending NewsAnalyst UpgradeAnalyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.4905 of 5 stars$14.73+0.0%$17.00+15.4%+10.6%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.5574 of 5 stars$175.69+7.9%$216.07+23.0%+30.2%$10.71B$368.70M-24.75640Analyst ForecastAnalyst RevisionMRNAModerna4.526 of 5 stars$27.05+1.8%$53.58+98.1%-81.3%$10.46B$3.14B-2.913,900VTRSViatris2.5476 of 5 stars$8.69-1.1%$10.50+20.8%-15.6%$10.20B$14.33B-11.7437,000QGENQiagen3.2034 of 5 stars$44.89-0.5%$48.42+7.9%+9.2%$9.98B$2.00B125.006,030BPMCBlueprint Medicines1.1596 of 5 stars$127.79+26.1%$125.69-1.6%+21.4%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.4301 of 5 stars$11.17+1.6%$17.50+56.7%+6.7%$7.97B$29.05M-74.46860 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SWTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SWTX Stock Free SWTX Stock Alerts